Why Biohaven Catapulted 25% — And Why It Might Not Be Done Sprinting
Biohaven stock catapulted Thursday after the FDA said it would review the company's embattled drug, troriluzole.
The post Why Biohaven Catapulted 25% — And Why It Might Not Be Done Sprinting appeared first on Investor's Business Daily .